Biogen Inc (BIIB)
201.62
-0.84
(-0.42%)
USD |
NASDAQ |
Apr 26, 09:43
Biogen Free Cash Flow (Quarterly): 432.30M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 432.30M |
December 31, 2023 | -52.70M |
September 30, 2023 | 504.80M |
June 30, 2023 | 400.00M |
March 31, 2023 | 383.70M |
December 31, 2022 | -262.40M |
September 30, 2022 | 601.90M |
June 30, 2022 | 697.70M |
March 31, 2022 | 103.90M |
December 31, 2021 | 769.80M |
September 30, 2021 | 743.40M |
June 30, 2021 | 1.155B |
March 31, 2021 | 676.40M |
December 31, 2020 | -468.10M |
September 30, 2020 | 1.097B |
June 30, 2020 | 1.844B |
March 31, 2020 | 1.206B |
December 31, 2019 | 1.695B |
September 30, 2019 | 1.605B |
June 30, 2019 | 1.777B |
March 31, 2019 | 1.332B |
December 31, 2018 | 1.670B |
September 30, 2018 | 1.545B |
June 30, 2018 | 834.50M |
March 31, 2018 | 1.252B |
Date | Value |
---|---|
December 31, 2017 | 1.223B |
September 30, 2017 | 1.349B |
June 30, 2017 | 846.40M |
March 31, 2017 | -830.00M |
December 31, 2016 | 1.399B |
September 30, 2016 | 710.60M |
June 30, 2016 | 890.00M |
March 31, 2016 | 860.30M |
December 31, 2015 | 1.048B |
September 30, 2015 | 659.90M |
June 30, 2015 | 917.40M |
March 31, 2015 | 635.20M |
December 31, 2014 | 797.70M |
September 30, 2014 | 851.49M |
June 30, 2014 | 926.59M |
March 31, 2014 | 50.32M |
December 31, 2013 | 790.37M |
September 30, 2013 | 591.73M |
June 30, 2013 | -2.692B |
March 31, 2013 | 145.65M |
December 31, 2012 | 438.87M |
September 30, 2012 | 483.72M |
June 30, 2012 | 562.68M |
March 31, 2012 | 140.07M |
December 31, 2011 | 403.53M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-468.10M
Minimum
Dec 2020
1.844B
Maximum
Jun 2020
745.44M
Average
687.05M
Median
Free Cash Flow (Quarterly) Benchmarks
Eli Lilly and Co | -1.963B |
Bristol-Myers Squibb Co | 3.922B |
Gilead Sciences Inc | 1.954B |
AbbVie Inc | 4.548B |
Regeneron Pharmaceuticals Inc | 776.20M |